TRX Archives - DirectorsTalk

Tissue Regenix Group: Profitable and Cash-Generating Growth Strategy 2024

11th April 2024

Tissue Regenix Group PLC (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a

Tissue Regenix results demonstrate success of TRX’s “4S” strategy

19th September 2023

Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a

Tissue Regenix: Turning profitable and cash-generative

6th April 2023

Tissue Regenix: Operating leverage

27th September 2022

Tissue Regenix Group plc (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad

Tissue Regenix has another six months of strong sales growth under its belt (LON:TRX)

12th August 2022

Hardman and Co’s Dr Martin Hall discusses Tissue Regenix Group plc in this exclusive interview with DirectorsTalk.

Tissue Regenix significantly undervalued which should correct (VIDEO)

9th August 2022

Tissue Regenix Group plc (LON:TRX) is the topic of conversation when Dr Martin Hall joins DirectorsTalk Interviews. Martin reminds us of what the company does, summerises the key details from its

Tissue Regenix: Strong 1H’22 sales suggest upside potential

20th July 2022

Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a

Tissue Regenix: On pathway to sustainability

19th April 2022

Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a

Tissue Regenix: Faster-than-anticipated recovery

20th October 2021

Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a

Tissue Regenix Analyst Q&A: New capacity now on stream (LON:TRX)

13th July 2021

Hardman and Co’s Dr Martin Hall discusses Tissue Regenix Group plc in this exclusive interview with DirectorsTalk.

Be sure to check our sister interview main ratings news website

TRX

Tissue Regenix Group: Profitable and Cash-Generating Growth Strategy 2024

Tissue Regenix results demonstrate success of TRX’s “4S” strategy

Tissue Regenix: Turning profitable and cash-generative

Tissue Regenix: Operating leverage

Tissue Regenix has another six months of strong sales growth under its belt (LON:TRX)

Tissue Regenix significantly undervalued which should correct (VIDEO)

Tissue Regenix: Strong 1H’22 sales suggest upside potential

Tissue Regenix: On pathway to sustainability

Tissue Regenix: Faster-than-anticipated recovery

Tissue Regenix Analyst Q&A: New capacity now on stream (LON:TRX)

Q&As

Cerillion’s Louis Hall on FY results, market potential and future outlook (LON:CER)

Ilika CEO highlights growth, Cirtec partnership and market opportunities (LON:IKA)

Dekel Agri-Vision’s Lincoln Moore on cashew growth and 2025 goals

Touchstone Exploration CEO on Cascadura results, Rio Claro block and 2025 plans (LON:TXP)

ICG Enterprise Trust: Strong portfolio growth, increased investments and resilient strategy

Firering Strategic Minerals targets Q4 commissioning and Limeco expansion (LON:FRG)

Funds

Building a strong data economy for Europe’s future

Real estate investment opportunity for diversified portfolios

Exploring opportunities in fixed income investments

Understanding tax reform and its impact

Volta Finance share price rises as performance returns hit 18.4% YTD (LON:VTA)

Emerging markets show positive momentum amid economic uncertainty

Presentations

Ilika plc: A New Era in Solid-State Battery Innovation – 2024 Investor Presentation

Time Finance PLC Strong Growth and Strategic Progress: A Message from CEO Ed Rimmer

Pulsar Helium Inc.: A Pioneering Force in the Helium Industry with High-Concentration Discoveries

Pennant International Maximising operational efficiency

Norcros Results Year ended 31 March 2024, Strategic Success and Sustainable Growth

SAE Renewables Future Strategy to 2035 and Investment Case by Graham Reid CEO

Broker Talk

Duke Capital: Unlocking growth with strategic equity raise

Volta Finance: Robust returns and discounted value highlight investment opportunity

Shield Therapeutics: Strong H1 ’24 Sales and Cashflow Outlook for H2 ’25

City of London Investment Company sees positive growth in Q4 and FY24 FUM

Expertise and strategic asset management in an under-supplied market

Global perspective and market positioning of pawnbroking for H&T Group